ICVTS Click here for other ICVTS advertising opportunities
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Interact CardioVasc Thorac Surg 2008;7:107-110. doi:10.1510/icvts.2007.160473
© 2008 European Association of Cardio-Thoracic Surgery

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Stefan B. Watzka
Franz Lax
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Watzka, S. B.
Right arrow Articles by Müller, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Watzka, S. B.
Right arrow Articles by Müller, M. R.
Related Collections
Right arrow Pleura
Right arrow Lung - basic science

Institutional report - Experimental

Reactivity of integrin-linked kinase in human mesothelial cell proliferation{star}

Stefan B. Watzkaa,*, Ulrike Setineka, Monika Hubera, Heidi Cantonatia, Franz Laxa, Sonja Watsona, Günter Weigelb and Michael R. Müllera

a Division of Thoracic Surgery, Otto Wagner Hospital, Sanatoriumstraße 2, 1140 Vienna, Austria
b Vienna General Hospital, Vienna, Austria

*Corresponding author. Tel.: (+431) 91060-44008; fax: (+431) 4023570.

E-mail address: s.watzka{at}utanet.at (S.B. Watzka).

Integrin-linked kinase (ILK) is a protein kinase that links integrins and growth factors to a range of signalling pathways. ILK expression and activity are increased in a variety of human cancers. However, little is known regarding the role of ILK in malignant pleural mesothelioma (MPM). In this study, we assessed the expression of ILK in samples of human MPM, and compared it with the expression of epidermal growth factor receptor (EGFR). Thirty-four samples of human malignant mesothelioma were stained with a polyclonal antibody against ILK. Two independent observers evaluated the morphological pattern and intensity of staining. The findings have been compared with the patient's characteristics. Most MPM and mesothelial cell proliferation samples (87.9%) showed cytoplasmic ILK staining of varying intensity. Normal mesothelial cells and normal lung parenchyma did not stain for ILK at all. Conversely, the percentage of positive EGFR staining was somewhat lower (75.8%). The ILK-positive patients were significantly older than the ILK-negative patients. Here we report for the first time that ILK is indeed expressed in malignant mesothelioma. For further validation of a causal association between ILK and neoplastic mesothelial transformation, these immunohistochemical results should be supplemented with clinical and molecular biological data.

Key Words: Mesothelioma; Integrin-linked kinase; Immunohistochemistry; Epidermal growth factor receptor




This article has been cited by other articles:


Home page
Am. J. Respir. Cell Mol. Bio.Home page
N. H. Heintz, Y. M. W. Janssen-Heininger, and B. T. Mossman
Asbestos, Lung Cancers, and Mesotheliomas: From Molecular Approaches to Targeting Tumor Survival Pathways
Am. J. Respir. Cell Mol. Biol., February 1, 2010; 42(2): 133 - 139.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2008 European Association for Cardio-thoracic Surgery